EXHIBIT 10.19
*** TEXT OMITTED AND FILED SEPARATELY
PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST
UNDER 17 C.F.R. SECTION 200.80(b)(4)
AND RULE 406 UNDER THE SECURITIES
ACT OF 1933, AS AMENDED
AMENDMENT TO AGREEMENT
THIS AMENDMENT TO AGREEMENT (the "Amendment") is made and entered into
effective as of January 30, 2004 (the "Amendment Effective Date"), by and
between STRUCTURAL GENOMIX, INC., a corporation organized and existing under the
laws of the State of Delaware and having its principal place of business located
at 00000 Xxxxxxx Xxxxxx, Xxx Xxxxx, XX 00000 ("SGX") and XXX XXXXX AND COMPANY.,
a corporation organized and existing under the laws of the state of Indiana and
having its principal place of business at Lilly Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx,
Xxxxxxx 00000, ("Lilly"). Lilly and SGX may be referred to herein as a "Party"
or, collectively, as "Parties".
RECITALS
X. Xxxxx and SGX have entered into a Collaboration and License
Agreement effective April 14, 2003 as amended July 1, 2003, (the "Agreement")
under which the Parties have agreed to conduct a collaborative research program.
B. The Parties desire to amend the terms of the Agreement as provided
in this Amendment.
NOW, THEREFORE, the Parties agree as follows:
1. AMEND SECTION 5.5(a). Section 5.5(a) of the Agreement is hereby amended to
delete the final sentence in its entirety and replace it with the following::
"Notwithstanding anything to the contrary in this Agreement: (i) this Section
5.5(a) shall not apply to the Collaboration Targets: [...***...], [...***...],
[...***...], [...***...], [...***...] and such other Collaboration Targets as
Lilly or any Lilly representative on the JSC may from time to time add to this
list on written notice to SGX; and (ii) SGX shall have the right at all times to
use and practice Collaboration Technology relating to any Collaboration Target
which Lilly or any Lilly representative on the JSC confirms in writing to SGX is
not a drug target, for drug discovery purposes on its own behalf or under
collaborations with third parties who are [...***...] for such activities."
Lilly hereby confirms to SGX that members of the [...***...] family and
[...***...] are not drug targets.
2. FULL FORCE AND EFFECT. This Amendment, effective as of the Amendment
Effective Date, amends the terms of the Agreement and is deemed incorporated
into, and governed by all other terms of, the Agreement. The provisions of the
Agreement, as amended by this Amendment, remain in full force and effect. To the
extent that the Agreement is explicitly amended by this Amendment, the terms of
the Amendment will control where the terms of the Agreement are contrary to or
conflict with the following provisions. Where the Agreement is not explicitly
amended, the terms of the Agreement will remain in force.
IN WITNESS WHEREOF, the Parties have executed this Amendment in
duplicate originals by their authorized officers as of the date and year first
above written.
XXX XXXXX AND COMPANY STRUCTURAL GENOMIX, INC.
By: /s/ Xxxxxx X. Xxxx By: /s/ Xxxxxxx X. Xxxxxx
--------------------------------------------------- --------------------------------------------------------
Title: Executive Vice President, Science and Technology Title: Vice President, Finance
--------------------------------------------------- ------------------------------------------------------
***CONFIDENTIAL TREATMENT REQUESTED
